Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30214003 | 1.00 | CA1 (0.55) | CA1CA12CA9CYP3A4PTGS2 | |
| SCHEMBL186502 | 0.82 | ALDH1A1 (0.59) | CA1CA12CA9CYP3A4CYP1A1 | |
| Flamenol SCHEMBL69428 | 0.82 | CYP3A4 (0.62) | CA1CYP3A4PTGS2CYP1A1CYP1B1 | |
| SCHEMBL233829 | 0.82 | ALDH1A1 (0.69) | CA1CYP3A4PTGS2CYP1A1CYP1B1 | |
| SCHEMBL168353 | 0.82 | ALDH1A1 (0.69) | CA1CA12CA9CYP3A4PTGS2 | |
| Flamenol SCHEMBL3190965 | 0.79 | CYP3A4 (0.59) | CA1CYP3A4PTGS2CYP1A1CYP1B1 | |
| Methane SCHEMBL28126699 | 0.79 | ALDH1A1 (0.56) | CA1CA12CA9CYP3A4CYP1A1 | |
| SCHEMBL7234709 | 0.78 | ALDH1A1 (0.55) | CA1CYP3A4CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL17204038 | 0.76 | CA12 (0.48) | CA1CA12CA9ALDH1A1TP53 | |
| SCHEMBL2395245 | 0.76 | CA12 (0.48) | CA1CA12CA9CALM1HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292494-A | Isoquinoline carboxylic acid compound and preparation method and application thereof | 江苏苏中药业集团股份有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2018-07-24 | — | — | US | claimed |
| EP-3134391-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2017-03-01 | — | — | EP | claimed |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | BASF SE (DE) | 2017-02-16 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | THE CLEVELAND CLINIC FOUNDATION | 2016-11-03 | — | — | US | claimed |
| WO-2015162166-A1 | DIAMINOTRIAZINE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2015-10-29 | — | — | WO | claimed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | CA1 2063/4885CA12 2005/4885CA9 3109/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | CA1 2063/4885CA12 2005/4885CA9 3109/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | CA1 1515/4885CA12 1772/4885CA9 2714/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | CA1 2063/4885CA12 2005/4885CA9 3109/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | CA1 1515/4885CA12 1772/4885CA9 2714/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | CA1 2063/4885CA12 2005/4885CA9 3109/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | CA1 563/4885CA12 958/4885CA9 2537/4885 |
| US-10029992-B2 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | CA1 965/4885CA12 2929/4885CA9 4092/4885 |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | VEGFA, ALDH1A2, PGF | CA1 2140/4885CA12 977/4885CA9 367/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | CA1 628/4885CA12 2849/4885CA9 3957/4885 |
| US-20170044114-A1 | Diaminotriazine compounds and their use as herbicides | NR4A3, CBR3, RCOR3 | CA1 986/4885CA12 2954/4885CA9 4119/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | CA1 346/4885CA12 1254/4885CA9 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.